0.000USD0.000åå ŽååŒÂ 07/24, 09:30 (ET)
296.80BæäŸ¡ç·é¡
22.22çŽè¿12ã¶æPER
äž»èŠããŒã¿
151.700å§å€
156.935é«å€
2.11Måºæ¥é«
22.22çŽè¿12ã¶æPER
16.38äºæ³PER
3.081çŽè¿12ã¶æé
åœ
0.11%売買å転ç
153.080忥çµå€
151.440å®å€
192.86M売買代é
24.86æ ªäŸ¡åçç
7.14PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
1.97%çŽè¿12ã¶æé
åœå©åã
12.37%ç·è³ç£å©çç
170.46052é±é«å€
0.96åºæ¥é«æ¯ç%
11.94BçŽå©ç
1.90Bæ ªåŒæ°
7.02681æ ªåœããå©çïŒEPSïŒ
0.47ããŒã¿å€
35.21%èªå·±è³æ¬å©çç
111.06052é±å®å€
3.59%æ¯ãå¹
75.39%ç²å©çç
296.80BæäŸ¡ç·é¡
-0.03ãªã¹ã¯ãªã¿ãŒã³
0.89%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-23 äž»èŠã€ã³ãµã€ã
Novartis AGã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸããå»è¬åæ¥çã§ã®é äœã¯155äž75äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããããŒã«ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯144.15ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯å®å®æšç§»ãšäºæ³ãããŸããéå»1ãæã®æ ªåŒåžå Žã®ããã©ãŒãã³ã¹ã¯å¹³åçã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Novartis AGã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Novartis AGã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Novartis AG ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
ææšî
ææš
売ã(1)
äžç«(3)
è²·ã(2)
ç§»åå¹³å
売ã(0)
äžç«(0)
è²·ã(6)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Novartis AGã®äŒæ¥æ
å ±î
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
äŒæ¥ã³ãŒãNVS
äŒæ¥åNovartis AG
æé«çµå¶è²¬ä»»è
ãCEOãNarasimhan (Vasant)
ãŠã§ããµã€ãhttps://www.novartis.com/
æ ªäž»çµ±èšî
ãããã質å
Novartis AGïŒNVSïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îNovartis AGïŒNVSïŒã®çŸåšã®æ ªäŸ¡ã¯156.15ã§ãã
Novartis AGã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îNovartis AGã®ãã£ãã«ãŒã·ã³ãã«ã¯NVSã§ãã
Novartis AGã®52é±é«å€ã¯ãããã§ããïŒ
îNovartis AGã®52é±é«å€ã¯170.46ã§ãã
Novartis AGã®52é±å®å€ã¯ãããã§ããïŒ
îNovartis AGã®52é±å®å€ã¯111.06ã§ãã
Novartis AGã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îNovartis AGã®æäŸ¡ç·é¡ã¯296.80Bã§ãã
Novartis AG (NVS) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãNovartis AGïŒNVSïŒã®ç·åè©äŸ¡ã¯signal_holdã§ãç®æšæ ªäŸ¡ã¯144.15ã§ãã
Novartis AG (NVS) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îNovartis AGïŒNVSïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯7.21ã§ãã